{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:22:07Z","timestamp":1792671727455,"version":"4.5.0"},"reference-count":14,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urol Int"],"abstract":"<jats:p>Introduction: We examined the impact of prostate-specific antigen (PSA) response, which is associated with survival, on patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen receptor signal inhibitors (ARSIs). Methods: We retrospectively reviewed 82 patients with mHSPC who received upfront ARSI treatment. The primary endpoint was PSA progression-free survival (PFS). Patients whose PSA levels decreased to \u22640.2 ng\/mL at 3 months after ARSI initiation were classified as deep early, those with &gt;0.2\u2013\u22641.0 ng\/mL as early, and others as non-PSA responders. Results: The median age of patients was 73 years old, and the median baseline PSA value was 361 ng\/mL. Among 82 patients, 32 (39%), 16 (20%), and 34 (41%) were categorized into deep early, early, and non-early PSA responders, respectively. There was a significant association between PSA response status, hemoglobin, and PSA value. During follow-up (median, 23.0 months), 31 (37.8%) patients experienced PSA progression. The PSA progression rates of the deep early, early, and non-early PSA responders were 15.6%, 31.2%, and 61.8% (p &lt; 0.001), and their 2-year PSA PFS rates were 90.5%, 70.7%, and 38.9%, respectively. Conclusion: An early PSA response within 3 months of ARSI initiation was associated with PSA progression in patients with mHSPC.<\/jats:p>","DOI":"10.1159\/000546327","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T12:01:59Z","timestamp":1747915319000},"page":"62-68","source":"Crossref","is-referenced-by-count":1,"title":["Impact of an Early Prostate-Specific Antigen Response on Biochemical Progression during Upfront Androgen Receptor Signal Inhibitor Therapy for Metastatic Hormone-Sensitive Prostate Cancer"],"prefix":"10.1159","volume":"110","author":[{"given":"Asumi","family":"Nirazuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Tsujioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Setoguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaku","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601242"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119115"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903307"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.03.001"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.02.009"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.11.021"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14258"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00367-1"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00193"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24064"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200195"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13253"}],"container-title":["Urologia Internationalis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000546327","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000546327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T17:02:20Z","timestamp":1770051740000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000546327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,2]]},"published-print":{"date-parts":[[2026,2,3]]}},"URL":"https:\/\/doi.org\/10.1159\/000546327","archive":["Portico"],"relation":{},"ISSN":["0042-1138","1423-0399"],"issn-type":[{"value":"0042-1138","type":"print"},{"value":"1423-0399","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]}}}